Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 in advanced solid tumors
NCT05278832Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS-31905 in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose limiting toxicities at 2 years and Maximum tolerated Dose at 2 years. Status: unknown.
02
Drugs
QLS-31905
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05278832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278832.